Abstract
Background: Elevated pre-treatment neutrophil-to-lymphocyte ratio (NLR) may reflect immune dysfunction and is negatively prognostic in cancer patients treated with immunotherapy, but it is unclear if NLR is predictive of immunotherapy benefit. Methods: We identified stage III non-small-cell lung cancer (NSCLC) patients treated with definitive chemoradiation and adjuvant durvalumab within the national Veterans Affairs system from 2017 to 2021. We compared the prognostic value of NLR measured before durvalumab start to a control group of stage III NSCLC patients treated with definitive chemoradiation alone from 2015 to 2016 (no-durvalumab group) before the approval of adjuvant durvalumab. We estimated the predictive value of NLR through the statistical interaction of durvalumab group by NLR level. Outcomes included progression-free survival (PFS) and overall survival (OS). Results: The primary analysis for NLR included 821 durvalumab patients and 445 no-durvalumab patients. Higher NLR was associated with inferior PFS in both groups (no-durvalumab: adjusted HR [aHR] 1.14 per 7.43 unit increase in NLR, 95% confidence interval [CI] 1.06–1.23; durvalumab: aHR 1.42, 95% CI 1.23–1.64), though this effect was greater in durvalumab patients (p for interaction = 0.009). Similar results were found for OS (no-durvalumab: aHR 1.16, 95% CI 1.09–1.24; durvalumab: aHR 1.48, 95% CI 1.25–1.76; p for interaction = 0.010). Absolute lymphocytes, eosinophils, and basophils were not prognostic in either group. Estimates of durvalumab treatment efficacy suggested declining efficacy with higher NLR. Conclusion: Pre-treatment NLR is especially prognostic among stage III NSCLC patients treated with adjuvant immunotherapy compared to control patients treated without immunotherapy and may be a predictive biomarker of immunotherapy benefit.
Original language | English (US) |
---|---|
Pages (from-to) | 35-41 |
Number of pages | 7 |
Journal | Lung Cancer |
Volume | 163 |
DOIs | |
State | Published - Jan 2022 |
Funding
G.W.S. serves an uncompensated position on the Board of Directors for the Optimal Cancer Alliance. A.Q. receives grant/research support from Merck and Clovis. A.K.B, K.S. L.Z. D.E. M.D.G. and N.R. declare no conflicts of interest. This work was funded by R21 CA252010, I01 BX005267, MRA 689853, and LUNGevity 2021-07 to M.D.G. as well as I01 CX001560, IO1 CX002007, and CU-20-002 to N.R. G.W.S. serves an uncompensated position on the Board of Directors for the Optimal Cancer Alliance. A.Q. receives grant/research support from Merck and Clovis. A.K.B, K.S., L.Z., D.E., M.D.G. and N.R. declare no conflicts of interest. This work was funded by R21 CA252010, I01 BX005267, MRA 689853, and LUNGevity 2021-07 to M.D.G. as well as I01 CX001560, IO1 CX002007, and CU-20-002 to N.R.
Keywords
- Durvalumab
- Immunotherapy
- Neutrophil-to-lymphocyte ratio
- Non-small-cell
- stage III
ASJC Scopus subject areas
- Oncology
- Pulmonary and Respiratory Medicine
- Cancer Research